Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in patients with Fabry disease: Two-year interim results from the ongoing phase 3 BRIGHT51 open-label extension study
Year: 2023
Type: article
Authors: John Bernat, Myrl D. Holida, Nicola Longo, Ozlem Goker-Alpan, Eric Wallace, Patrick B. Deegan, Camilla Tøndel, Francois J. Eyskens, Ulla Feldt-Rasmussen, Derralynn Hughes, Antonio Pisani, Rossana Rocco, Einat Brill Almon, Sari Alon, Raul Chertkoff, David G. Warnock, Stephen Waldek, William R. Wilcox
Institutions: University of Iowa Hospitals and Clinics, University of Iowa Stead Family Children’s Hospital, University of Utah, Lysosomal and Rare Disorders Research and Treatment Center, University of Alabama at Birmingham, Addenbrooke's Hospital, University of Bergen, Antwerp University Hospital, University of Copenhagen, University College London, University of Naples Federico II, Chiesi (Italy), Protalix BioTherapeutics (Israel), University of Sunderland, Emory University
Language: English
Subfield: Physiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4319459676